Tatyana Kushner, MD, is an associate professor of medicine in the division of gastroenterology and hepatology at Weill Cornell Medicine.

Brelovitug, an investigational monoclonal antibody targeting hepatitis B surface antigen (HBsAg), met the primary end point in adults with chronic hepatitis D, according to late-breaking phase 3 AZURE-1 data presented by Tatyana Kushner, MD, MSCE, at 

“It was actually quite safe and very well tolerated,” Kushner, associate professor of medicine in the Department of Gastroenterology at Weill Cornell Medicine in New York, New York, told HCPLive.

Hepatitis delta virus (HDV) relies on HBsAg to infect liver cells and causes the most aggressive form of viral hepatitis.

 Bulevirtide (Hepcludex) received FDA accelerated approval in May 2026 as the first US treatment, ending reliance on off-label pegylated interferon.

Brelovitug for Hepatitis D: Phase 3 AZURE-1 Results

Brelovitug Meets Primary End Point in Phase 3 AZURE-1 for Hepatitis D

AZURE-1 randomized 153 participants to brelovitug 300 mg weekly self-administered at home, 900 mg every 4 weeks in clinic, or delayed treatment. At week 24, the combined virologic and ALT response end point was achieved by 56% of participants in the weekly group and 45% in the monthly group, compared with 0% with delayed treatment (both 

 < .0001). HDV RNA fell by a mean 3.4 log

There were no treatment-related serious adverse events, grade 3 or higher adverse events, or discontinuations due to adverse events. Injection site reactions and flu-like illness were the most common events.

Notably, 41% of participants had cirrhosis, 20% had at least probable clinically significant portal hypertension, and HIV coinfection was permitted.

“Having this type of patient population really helps us have comfort in being able to prescribe this regimen to a patient population that we see in our practice,” Kushner said.

Watch the full interview to hear Kushner discuss how weekly vs monthly dosing may fit patient preferences, what week 96 follow-up must answer, and the outcomes that matter most beyond viral load.

Kushner T, Yardeni D, Dobryanska M, et al. Efficacy and safety of brelovitug monotherapy for chronic hepatitis D: primary 24-week results from the phase 3 AZURE-1 study. Late-breaking abstract presented at: The Liver Meeting 2026; November 5-9, 2026; Denver, CO.

Campbell P. Bulevirtide receives historic first FDA approval for chronic hepatitis delta. HCPLive. May 22, 2026. Accessed November 11, 2026. 

https://www.hcplive.com/view/bulevirtide-historic-first-fda-approval-chronic-hepatitis-delta

Videos

Late-breaking data presented at AASLD 2026 showed brelovitug met the phase 3 primary endpoint in chronic hepatitis D, with no treatment-related serious adverse events.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Hepatology

Brelovitug for Chronic Hepatitis D: Phase 3 AZURE-1 Results

Joseph Rossano, MD, MS, is the co-director of the Cardiac Center and chief of the division of cardiology at the Children’s Hospital of Philadelphia, as well as the Jennifer Terker Endowed Chair in Pediatric Cardiology.

Mavacamten sustainably reduced left ventricular outflow tract (LVOT) obstruction in pediatric patients with 

obstructive hypertrophic cardiomyopathy (oHCM)

 with a favorable safety profile, according to long-term data from SCOUT-HCM.

Mavacamten Sustainably Reduces LVOT Gradient in Pediatric oHCM Over 56 Weeks

American Heart Association (AHA) Scientific Sessions 2026

 in Chicago, Illinois, by Joseph Rossano, MD, MS, co-director of the cardiac center, chief of the division of cardiology, and associate chair for external affairs at Children’s Hospital of Philadelphia. In an exclusive interview with 

, Rossano explained his thoughts on mavacamten’s regulatory approval and the next steps for investigators to take.

“I think that what mavacamten has done for hypertrophic cardiomyopathy in children is really foundational and paradigm-changing,” Rossano told 

. “For the first time, we have a medication that’s really targeted for the underlying pathophysiology, and we have very good data from children with the disorder.”

SCOUT-HCM was a randomized, double-blind, placebo-controlled study evaluating mavacamten in patients aged 12 to <18 years with symptomatic oHCM. The only eligibility criteria for the trial were a diagnosis of HCM and presence of LVOT obstruction and symptoms. Patients with phenocopy diseases resulting in myocardial hypertrophy unrelated to sarcomere dysfunction, as well as left ventricular ejection fraction <50% in the 6 months prior to enrollment, were excluded.

Patients were randomly assigned in a 1:1 ratio to receive either mavacamten or placebo, both at a range of 1 to 15 mg. The primary endpoint was change from baseline in Valsalva LVOT gradient at week 28, while secondary outcomes included change from baseline in resting LVOT gradient, maximal wall thickness, post-exercise peak LVOT gradient, and early mitral inflow velocity and mitral annular early diastolic velocity, among others.

A total of 44 patients were enrolled in the study, of whom 23 were assigned to mavacamten and 21 to placebo. The mean age was 14.7 (+/- standard deviation [SD], 1.7) years in the mavacamten arm and 14.6 +/- 1.7 years in the placebo arm. By week 28, the least-squares mean change in Valsalva LVOT gradient was -48.5 mmHg in the mavacamten arm and -0.5 mmHg in the placebo arm (difference, -48 mmHg; 95% CI, -67.7 to -28.3; 

 <.001). The incidence of adverse events was similar between both groups.

Rossano and colleagues then began the present active-treatment phase out to 56 weeks. Patients assigned to mavacamten initially continued treatment, while those assigned to placebo crossed over to 2.5 mg or 5 mg mavacamten daily, depending on body weight. The exploratory efficacy endpoints for this portion of the trial included changes from baseline or week 28 to week 56 in Valsalva and resting LVOT gradients and maximal wall thickness, among others.

Of the 44 patients initially included, 43 completed the initial 28-week double-blind, placebo-controlled period and entered the active-treatment phase. Mean change from baseline to week 56 in Valsalva LVOT gradient was -48.1 mmHg in the treatment arm, while change from week 28 to 56 was -35.1 mmHg in the placebo-mavacamten arm. The team also recorded improvements in other efficacy endpoints, which were carried over from the placebo-controlled phase.

Ultimately, Rossano and colleagues determined that mavacamten successfully and safely reduced LVOT gradient over a long period of time, with a favorable safety profile. Rossano went on to discuss the next steps for investigating mavacamten in a real-world setting following its earlier regulatory approval for this population.

“We need to understand how the medication does in a larger group of patients, and I think that will be a very important part of the studies to come,” Rossano said. “We should get a very good sense of what the safety of the medication is, and somewhat of the efficacy of the medication, through the REMS program, but I think we really need other mechanisms to get more granular data to really understand the potential benefit and risks of the medication.”

Editors’ Note: Rossano reports disclosures with AskBio, Astellas, Bayer, Bristol Myers Squibb, CRI Biotech, and Merk.

Aronson R, Canter C, Desai M, et al. Outcomes of mavacamten treatment in pediatric patients with obstructive hypertrophic cardiomyopathy at 56 weeks: the SCOUT-HCM trial. Presented at the American Heart Association (AHA) Scientific Sessions 2026, Chicago, IL. November 6-9, 2026.

Bristol-Myers Squibb. A Study to Evaluate Mavacamten in Adolescents With Symptomatic Obstructive Hypertrophic Cardiomyopathy. ClinicalTrials.gov Identifier: NCT06253221. Updated December 19, 2025. Accessed November 11, 2026. 

https://clinicaltrials.gov/study/NCT06253221

Rossano JW, Canter C, Wolf CM, et al. Mavacamten in Adolescents with Obstructive Hypertrophic Cardiomyopathy. N Engl J Med. 2026 Jul 23;395(4):362-373. 

Joseph Rossano, MD, MPH, discusses the 56-week active-treatment period of the SCOUT-HCM trial, which demonstrated the sustainability of mavacamten’s effects.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Stroke

On the HCPLive stroke page, resources on the topics of medical news and expert insight into CVA can be found. Content includes articles, interviews, videos, podcasts, and breaking news on stroke medicine, and more.

Cardiomyopathy

Chari Cohen, DrPH, MPH, is the President of the Hepatitis B Foundation.

Most people living with hepatitis B who were taking antiviral therapy reported high adherence, while nearly two-thirds of those not on treatment were receiving no hepatitis B care at all, according to multinational survey data presented by Chari Cohen at 

“It is not silent for the people who have it,” Cohen, president of the Hepatitis B Foundation, told 

, describing the physical and emotional toll the disease takes even in the absence of liver damage.

Quality of Life in Hepatitis B: Global Survey Insights

Is HBV Really a Silent Disease? New Patient-Reported Data Suggests Otherwise

The ongoing longitudinal study surveyed 486 adults living with hepatitis B in 42 countries. Among the 50.9% taking antivirals, 86.2% reported taking medication daily as directed, and 84.4% were confident treatment was helping. Fatigue or weakness was the most commonly reported symptom (44.0%), and more than half of participants were highly concerned about liver-related illness and death. About 1 in 4 participants rated their relationship with their physician as fair or poor.

Among participants not taking antivirals, 63.7% were not engaged in any hepatitis B care, most often citing cost, limited access to clinicians or medication, or feeling healthy. Yet 73.5% said they would be very willing to start therapy if recommended.

Of the estimated 254 million people living with chronic hepatitis B worldwide in 2022, only 13% had been diagnosed and about 3% had received antiviral therapy.

 Cohen says closing that gap will require governments to prioritize hepatitis B elimination, as many did for hepatitis C. She also hopes follow-up data will help turn adherence from a reason to delay treatment into something clinicians can actively support.

Watch the full interview to hear Cohen discuss why patient-reported outcomes have long been missing from hepatitis B care, what later time points may show, and how shared decision-making can be put into practice.

Ibrahim Y, Freeland C, Cohen C. Hepatitis B patient-reported outcomes: multinational insights on quality of life and antiviral adherence. Presented at: The Liver Meeting 2026; November 5-9, 2026; Denver, CO.

Global Hepatitis Report 2024: Action for Access in Low- and Middle-Income Countries

. World Health Organization; 2024. Accessed November 11, 2026. 

https://www.who.int/publications/i/item/9789240091672

New survey data from 42 countries show high antiviral adherence among people with hepatitis B, but 64% of those untreated receive no hepatitis B care.

Hepatitis B

Hepatitis B page, resources on the topics of medical news and expert insight into HCV can be found. Content includes articles, interviews, videos, podcasts, and breaking news on hepatitis B virus research, treatment, and drug development.

Pharmacovigilance data on more than 300 pregnancies exposed to glecaprevir/pibrentasvir showed no cases of vertical transmission of 

 and no pattern of congenital anomalies, according to an analysis presented by Tatyana Kushner, MD, MSCE, at 

“From the data that we do see, overall it looks reassuring,” Kushner, associate professor of medicine in the Department of Gastroenterology at Weill Cornell Medicine in New York, New York, told 

Real-World Data Show Reassuring Pregnancy Outcomes With Glecaprevir/Pibrentasvir

HCV Treatment in Pregnancy, With Tatyana Kushner

Universal HCV screening during each pregnancy has been recommended in the US since 2020, and Kushner notes that more people are now diagnosed during pregnancy.

 AASLD/IDSA guidance states that treatment can be considered on an individual basis after discussing risks and benefits, but she says many clinicians remain hesitant without clearer safety data.

What Did the Pharmacovigilance Analysis Show?

Investigators reviewed 328 pregnancies with reported glecaprevir/pibrentasvir (Mavyret) exposure in AbbVie’s global pharmacovigilance database from July 2017 to March 2026. Among the 87 pregnancies with documented outcomes, 51.7% resulted in live births, 19.5% in elective abortions, and 28.7% in spontaneous abortions. Three live births were preterm, and 2 had congenital anomalies with no recurring pattern. Investigators reported that rates of spontaneous abortion and preterm birth were lower than those reported among pregnant individuals with HCV not exposed to direct-acting antivirals.

Kushner cautions that most exposures lacked outcome data and that adverse outcomes are more likely to be reported, which may skew results. Treatment was discontinued in 146 of 223 cases with available status, which investigators suggest may reflect a lack of shared decision-making.

Watch the full interview to hear Kushner discuss how conversations about treatment differ by trimester, when pausing therapy during the first trimester may be considered, and what prospective data are still needed.

Editors’ note: Kushner has relevant disclosures with Gilead, GSK, Madrigal, Ipsen, Mirum, and Eiger Biopharmaceuticals. 

Schillie S, Wester C, Osborne M, Wesolowski L, Ryerson AB. CDC recommendations for hepatitis C screening among adults—United States, 2020. 

Kushner T, Cave B, Marcinak J, et al. Pregnancy outcomes following glecaprevir/pibrentasvir exposure in pregnant women with hepatitis C: a pharmacovigilance analysis. Presented at: The Liver Meeting 2026; November 5-9, 2026; Denver, CO.

Pharmacovigilance data on 328 pregnancies exposed to glecaprevir/pibrentasvir presented at AASLD 2026 showed no vertical transmission and no pattern of congenital anomalies.

Hepatitis C

Hepatitis C page, resources on the topics of medical news and expert insight into HCV can be found. Content includes articles, interviews, videos, podcasts, and breaking news on hepatitis C virus research, treatment, and drug development.

Women's Health

On the HCPLive women's health page, resources on the topics of medical news and expert insight into obstetrics, gynecology, and women's related health can be found. Content includes articles, interviews, videos, podcasts, and breaking news on women's health, and more.

HCV Treatment in Pregnancy, With Tatyana Kushner, MD

 across all baseline PREVENT cardiovascular risk categories, according to an analysis of the CORALreef Lipids study.

Enlicitide Lowers LDL-C Consistently Across PREVENT CVD Risk Categories

 in Chicago, Illinois, by Christie Ballantyne, MD, chief of cardiology and cardiovascular research and director for cardiometabolic disease prevention at Baylor College of Medicine.

“One of the exciting things about enlicitide and the CORALreef program has been the consistency of data in the trials,” Ballantyne told 

 in an exclusive interview. “One of the things we always like to see is when you’re doing different trials and different subsets, you have consistent data. And I think this is an instance where we take a pretty straightforward therapy – it’s only one dose, 20 mg – and you’re getting substantial LDL-C reductions.”

CORALreef Lipids was a multinational, double-blind, randomized, placebo-controlled trial evaluating enlicitide’s efficacy in patients with a history of a major atherosclerotic cardiovascular disease (ASCVD) event who had elevated LDL-C levels. Patients were eligible for inclusion if they had LDL-C ≥55 mg/dL and were being treated with a moderate- or high-intensity statin, among other criteria. Those with a history of homozygous familial hypercholesterolemia or heart failure, or those who were undergoing an LDL-C apheresis program within 3 months prior to first study visit, were excluded.

Patients were randomly assigned in a 2:1 ratio to either enlicitide 20 mg or placebo daily for 52 weeks. The primary endpoint was mean percent change in LDL-C from baseline to week 24. Key secondary endpoints included mean percent change in LDL-C at week 52,and the mean percent change in non-HDL-C, apolipoprotein B (ApoB), and lipoprotein(a) (Lp(a)) levels at week 24.

A total of 2909 patients were enrolled in the trial, of whom 1935 were assigned to enlicitide and 969 to placebo. Mean age was 63 years, and mean LDL-C level at baseline was 96.1 mg/dL (+/- standard deviation [SD], 38.9 mg/dL). By week 24, mean LDL-C change was -57.1% (95% CI, -61.8 to -52.5) with enlicitide and 3% (95% CI, 0.9 to 5.1) with placebo. This represented an adjusted between-group difference of -55.8% (95% CI, -60.9 to -50.7; 

In the present analysis, Ballantyne and colleagues included a total of 843 patients, 573 from the enlicitide arm and 270 from the placebo arm. Baseline PREVENT 10-year risk was categorized as low (<3%), borderline (3 to 5%), intermediate (5 to <10%), or high (≥10%) risk. Percent change from baseline in LDL-C was assessed across PREVENT risk categories, while additional analyses evaluated the percent changes in ApoB, Lp(a), and non-HDL-C.

Of the included patients, 8.2% were categorized as low-risk, 18.3% as borderline, 44% as intermediate, and 29.5% as high risk. Mean age increased with PREVENT risk, rising from 48.8 to 70.4 years. At week 24, placebo-corrected mean percent changes from baseline in LDL-C were -62.6% in low-risk patients, -57.6% in borderline risk, -57.1% in intermediate risk, and -58% in high-risk PREVENT strata. Ballantyne and colleagues also saw reductions in Lp(a), ApoB, and non-HDL-C across all strata.

Ultimately, Ballantyne and colleagues determined that enlicitide effectively and consistently reduced LDL-C across all baseline PREVENT cardiovascular risk categories, with corresponding reductions in other key markers of cholesterol. Ballantyne addressed the implications of these data for the safety and efficacy of enlicitide, particularly in advance of the ongoing outcomes trial.

“There’s a very large outcomes trial that’s fully enrolled – we haven’t heard anything from that, but I think we can have enough confidence in what we have now,” Ballantyne said. “If someone doesn’t want to take an injectable, we have another option which gives the same efficacy as that injectable: an easy once-a-day pill.”

Editors’ Note: Ballantyne reports disclosures with Abbott, Amgen, Arrowhead, AstraZeneca, Eli Lilly, Genentech, and others.

Navar A, Banka P, Wumesh K, et al. Efficacy of Enlicitide on LDL-C Reduction Across PREVENT Cardiovascular Risk Categories in the Phase 3 CORALreef Lipids Study. Presented at the American Heart Association (AHA) Scientific Sessions 2026, Chicago, IL. November 6-9, 2026.

Merck Sharp & Dohme. A Study of Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-013) CORALreef Lipids. ClinicalTrials.gov Identifier: NCT05952856. Updated September 24, 2026. Accessed November 11, 2026. 

https://clinicaltrials.gov/study/NCT05952856

Navar AM, Mikhailova E, Catapano AL, et al. A placebo-controlled trial of the oral PCSK9 inhibitor enlicitide. New England Journal of Medicine. 2026;394(6):529-539. 

Christie Ballantyne, MD, discusses his analysis of the CORALreef Lipids trial, highlighting enlicitide’s effects on LDL-C, ApoB, Lp(a), and non-HDL-C.

Dyslipidemia

Martina J. Porter, MD, is a dermatologist at Beth Israel Deaconess Medical Center.

Long-term trial and real-world experience suggest tunnel responses can be durable, and even regress in some patients. The panel describes how patient-defined success and follow-up cadence guide decisions to continue or escalate therapy.

Video Series

HS Long-Term Outcomes: Durable Response, Tunnel Regression, and Monitoring

Nancy Reau, MD, is Professor of Internal Medicine, Richard B. Capps Chair of Hepatology, Associate Director of Solid Organ Transplantation, and Section Chief of Hepatology at Rush University Medical Center.

Podcasts

Jasmohan Bajaj, MD, MS, joins Nancy Reau, MD, and Kimberly Brown, MD, on who to screen for HE in clinic and how to prepare patients and families.

podcasts page features a feed of medical news and interview podcast series, including DocTalk, Lungcast, Derm Discussions, and Heart Trials.

Liver Lineup: Updates & Unfiltered Insights

Introducing Liver Lineup: Updates & Unfiltered Insights — an exciting new podcast delivering timely, candid perspectives on the most pressing topics in the fast-moving world of hepatology. Hosted by Nancy Reau, MD, and Kimberly Brown, MD, this series dives into the cutting edge of liver disease research, clinical care, and real-world practice.

Liver Lineup: Early Detection of Hepatic Encephalopathy

Gerard Criner, MD, is chair and professor of thoracic medicine and surgery at Lewis Katz School of Medicine at Temple University and director of the Temple Lung Center.

Articles

Gerard Criner, MD, reviews GOLD 2026 sessions on mucus plugs and inhaler technique, plus multimorbidity, exacerbation risk, and the 2027 GOLD Report.

COPD

COPD condition center page, resources on the topics of medical news and expert insight into chronic obstructive pulmonary disease can be found. Content includes articles, interviews, videos, podcasts, and breaking news on COPD research, treatment, and drug development.

Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

Q&A: Mucus Plugging, Multimorbidity, and GOLD 2027, With Gerard Criner, MD

Binu John, MD, MPH, is an associate professor of medicine and chief of gastroenterology and hepatology at the University of Miami

ALTUS data show the multi-target HCC blood test score tracks tumor size, Milan status, and LI-RADS category rather than liver disease severity.

HCC Blood Test Score Tracks Tumor Size, Not Liver Disease Severity

Tim Smith joined the MJH Life Sciences team in 2022 and is currently an associate editor for 

. He is also the executive producer of two podcasts: 

. Previously, he was the producer of the Lungcast podcast. He graduated from UC Berkeley and worked in multimedia journalism as a staff writer prior to joining MJH. You can contact him at tsmith@mjhlifesciences.com.

Dupilumab cut new or worsening allergies by 34% vs placebo in a 12-trial atopic dermatitis meta-analysis, suggesting it may slow the atopic march.

Atopic Dermatitis

Atopic Dermatitis condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatitis research, treatment, and drug development.

Dupilumab May Slow Atopic March in Atopic Dermatitis: Meta-Analysis

Evan Dellon, MD, MPH, is a professor in the division of gastroenterology and hepatology and director of the Center for Esophageal Diseases and Swallowing at UNC School of Medicine.

The most effective EoE therapy is one that controls disease and fits the patient's life. Age, caregiver involvement, treatment feasibility, efficacy, and safety all shape individualized treatment decisions.

Individualizing EoE Treatment Across the Age Spectrum

Long-term EoE control depends on both sustained response and a treatment patients can realistically maintain. Extended BOS data provide insight into histologic remission, endoscopic improvement, and tolerability over several years.

Long-Term Budesonide Oral Suspension Therapy in EoE

Muthiah Vaduganathan, MD, MPH, is a cardiologist specializing in cardiorenal metabolism at Brigham and Women's Hospital in Boston, MA. Vaduganathan is a member of Practical Cardiology's advisory board and co-host of Don't Miss a Beat, a podcast presented by Inside Cardiology.

Lp(a)HORIZON and ZEUS hit their biomarker targets but not MACE. Stephen Greene, MD, and Muthiah Vaduganathan, MD, MPH, unpack both at AHA 2026.

Don’t Miss a Beat

The Don't Miss a Beat podcast breaks down the latest evidence and clinical trial insights across cardiovascular, renal, and metabolic diseases. Don’t Miss a Beat as Steve Greene, MD, and Muthu Vaduganathan, MD, MPH, critically examine recent advances in clinical care and research with perspectives from global experts in the field.

Atherosclerotic Cardiovascular Disease

Don't Miss a Beat: What Lp(a)HORIZON and ZEUS Teach About Clinical Trial Science

Luke Laffin, MD, is the co-director of the Center for Blood Pressure Disorders, medical director of cardiac rehabilitation, and associate professor of medicine at Cleveland Clinic.

Luke Laffin, MD, discusses the open-label extension from Launch-HTN, which further investigated the efficacy of lorundrostat in uncontrolled hypertension.

Hypertension

The HCPLive hypertension page is a resource for medical news and expert insights on high blood pressure. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for hypertension, and more.

Transform-HTN: Lorundrostat Maintains Blood Pressure Reductions in Open-Label Extension 

Waldman Professor of Dermatology and Immunology, health system chair of the Kimberly and Eric J. Waldman Department of Dermatology, and director of the Laboratory for Inflammatory Skin Diseases at the Icahn School of Medicine at Mount Sina

Emma Guttman-Yassky, MD, discusses biomarker data showing rezpegaldesleukin's regulatory T-cell mechanism separates from placebo early.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Latest News

Brelovitug for Chronic Hepatitis D: Phase 3 AZURE-1 Results

Mavacamten Sustainably Reduces LVOT Gradient in Pediatric oHCM Over 56 Weeks

Is HBV Really a Silent Disease? New Patient-Reported Data Suggests Otherwise

HCV Treatment in Pregnancy, With Tatyana Kushner, MD

Enlicitide Lowers LDL-C Consistently Across PREVENT CVD Risk Categories